KR100624054B1 - (ｓ)-오메프라졸의 칼륨염 - Google Patents

(ｓ)-오메프라졸의 칼륨염 Download PDF

Info

Publication number
KR100624054B1
KR100624054B1 KR1020017009374A KR20017009374A KR100624054B1 KR 100624054 B1 KR100624054 B1 KR 100624054B1 KR 1020017009374 A KR1020017009374 A KR 1020017009374A KR 20017009374 A KR20017009374 A KR 20017009374A KR 100624054 B1 KR100624054 B1 KR 100624054B1
Authority
KR
South Korea
Prior art keywords
omeprazole
potassium salt
river
medium
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017009374A
Other languages
English (en)
Korean (ko)
Other versions
KR20010101699A (ko
Inventor
마스 닐슨
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20010101699A publication Critical patent/KR20010101699A/ko
Application granted granted Critical
Publication of KR100624054B1 publication Critical patent/KR100624054B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020017009374A 1999-01-28 2000-01-18 (ｓ)-오메프라졸의 칼륨염 Expired - Fee Related KR100624054B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9900274-3 1999-01-28
SE9900274A SE9900274D0 (sv) 1999-01-28 1999-01-28 New compound

Publications (2)

Publication Number Publication Date
KR20010101699A KR20010101699A (ko) 2001-11-14
KR100624054B1 true KR100624054B1 (ko) 2006-09-18

Family

ID=20414267

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017009374A Expired - Fee Related KR100624054B1 (ko) 1999-01-28 2000-01-18 (ｓ)-오메프라졸의 칼륨염

Country Status (40)

Country Link
US (1) US6511996B1 (https=)
EP (1) EP1149090B1 (https=)
JP (1) JP2002535401A (https=)
KR (1) KR100624054B1 (https=)
CN (1) CN1231477C (https=)
AR (1) AR022425A1 (https=)
AT (1) ATE236899T1 (https=)
AU (1) AU768676B2 (https=)
BG (1) BG65060B1 (https=)
BR (1) BR0007647A (https=)
CA (1) CA2357744C (https=)
CZ (1) CZ300504B6 (https=)
DE (1) DE60002042T2 (https=)
DK (1) DK1149090T3 (https=)
DZ (1) DZ3001A1 (https=)
EE (1) EE04240B1 (https=)
EG (1) EG23980A (https=)
ES (1) ES2193937T3 (https=)
HK (1) HK1041259B (https=)
HU (1) HU226766B1 (https=)
ID (1) ID30095A (https=)
IL (1) IL144107A0 (https=)
IS (1) IS2019B (https=)
MY (1) MY119095A (https=)
NO (1) NO319719B1 (https=)
NZ (1) NZ512804A (https=)
PL (1) PL197881B1 (https=)
PT (1) PT1149090E (https=)
RS (1) RS50200B (https=)
RU (1) RU2237666C2 (https=)
SA (1) SA00200895B1 (https=)
SE (1) SE9900274D0 (https=)
SI (1) SI1149090T1 (https=)
SK (1) SK285626B6 (https=)
TN (1) TNSN00017A1 (https=)
TR (1) TR200102138T2 (https=)
TW (1) TWI269795B (https=)
UA (1) UA71594C2 (https=)
WO (1) WO2000044744A1 (https=)
ZA (1) ZA200105526B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
EP1633736A1 (en) * 2003-05-05 2006-03-15 Ranbaxy Laboratories Limited Barium salt of benzimidazole derivative
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN103121992A (zh) * 2004-06-24 2013-05-29 阿斯利康(瑞典)有限公司 制备用于制备艾美拉唑钠盐的结晶修饰物的新方法
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
RU2372345C1 (ru) * 2005-10-26 2009-11-10 Ханми Фарм. Ко., Лтд. Стронциевая соль s-омепразола или ее гидрат, способ их получения и содержащая их фармацевтическая композиция
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
CN100384839C (zh) * 2006-02-17 2008-04-30 中国科学院上海有机化学研究所 [(取代的吡啶基)甲基]亚磺酰基-1h-苯并咪唑类化合物及其对映体的锌盐的制备方法
WO2007148213A2 (en) * 2006-06-21 2007-12-27 Glenmark Pharmaceuticals Limited Novel polymorph of esomeprazole potassium and process for its preparation
WO2008067037A2 (en) 2006-10-05 2008-06-05 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2086543A2 (en) 2006-10-27 2009-08-12 The Curators of the University of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
PE20120395A1 (es) 2006-12-04 2012-05-23 Bayer Ip Gmbh Sal de potasio cristalina de analogos de lipoxina a4
FR2920428B1 (fr) * 2007-08-29 2012-06-15 Univ Rouen Procede de dedoublement de sels de l'omeprazole
WO2009074997A2 (en) * 2007-12-10 2009-06-18 Lee Pharma Ltd. A novel process for the preparation of crystalline magnesium salt of (s)-omeprazole di hydrate
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
CN102884178B (zh) 2009-12-08 2014-12-03 科德克希思公司 拉唑化合物的合成
CN102319223B (zh) * 2011-09-21 2013-06-19 石药集团欧意药业有限公司 一种埃索美拉唑冻干制剂及其制备方法
CN102633776B (zh) * 2012-03-28 2014-06-18 中山市仁合药业有限公司 一种埃索美拉唑及其钠盐的制备方法
JP2025532389A (ja) 2022-10-04 2025-09-29 ザビリュク，アルセニー 大動脈弁の石灰化の抑制

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
SE8804629D0 (sv) * 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
EE03305B1 (et) 1994-07-08 2000-12-15 Astra Aktiebolag Paljuosaline tableteeritud annusvorm I
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
GB9423970D0 (en) 1994-11-28 1995-01-11 Astra Ab Oxidation
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B

Also Published As

Publication number Publication date
ZA200105526B (en) 2002-10-04
TNSN00017A1 (fr) 2005-11-10
EP1149090B1 (en) 2003-04-09
HK1041259B (en) 2003-10-24
NO319719B1 (no) 2005-09-05
AU2469400A (en) 2000-08-18
NZ512804A (en) 2003-07-25
NO20013665D0 (no) 2001-07-26
IL144107A0 (en) 2002-05-23
IS5989A (is) 2001-07-05
NO20013665L (no) 2001-07-26
ES2193937T3 (es) 2003-11-16
HUP0105313A2 (hu) 2002-05-29
RS50200B (sr) 2009-07-15
MY119095A (en) 2005-03-31
DE60002042D1 (de) 2003-05-15
AU768676B2 (en) 2003-12-18
WO2000044744A1 (en) 2000-08-03
SI1149090T1 (en) 2003-10-31
IS2019B (is) 2005-06-15
RU2237666C2 (ru) 2004-10-10
DZ3001A1 (fr) 2004-03-27
SK285626B6 (sk) 2007-05-03
UA71594C2 (uk) 2004-12-15
AR022425A1 (es) 2002-09-04
SE9900274D0 (sv) 1999-01-28
ID30095A (id) 2001-11-01
BG65060B1 (bg) 2007-01-31
US6511996B1 (en) 2003-01-28
CN1231477C (zh) 2005-12-14
SA00200895B1 (ar) 2006-11-11
EE04240B1 (et) 2004-02-16
HK1041259A1 (en) 2002-07-05
CZ300504B6 (cs) 2009-06-03
PL197881B1 (pl) 2008-05-30
EG23980A (en) 2008-02-27
PT1149090E (pt) 2003-07-31
SK10372001A3 (sk) 2002-02-05
TR200102138T2 (tr) 2001-12-21
CN1339034A (zh) 2002-03-06
HU226766B1 (en) 2009-09-28
DE60002042T2 (de) 2003-12-18
BG105841A (en) 2002-04-30
HUP0105313A3 (en) 2003-01-28
CZ20012730A3 (cs) 2002-02-13
DK1149090T3 (da) 2003-06-30
BR0007647A (pt) 2001-10-16
YU53801A (sh) 2004-07-15
CA2357744C (en) 2009-06-16
ATE236899T1 (de) 2003-04-15
EE200100395A (et) 2002-10-15
TWI269795B (en) 2007-01-01
KR20010101699A (ko) 2001-11-14
CA2357744A1 (en) 2000-08-03
EP1149090A1 (en) 2001-10-31
JP2002535401A (ja) 2002-10-22

Similar Documents

Publication Publication Date Title
KR100624054B1 (ko) (ｓ)-오메프라졸의 칼륨염
KR100527804B1 (ko) Ｓ-오메프라졸의 칼륨염
US7345061B2 (en) Alkylammonium salts of omeprazole and esomeprazole
US20120122933A1 (en) Compounds
US7326724B2 (en) Salts of omeprazole and esomeprazole I
KR100572297B1 (ko) 오메프라졸의 신규한 결정질 형태
MXPA01007516A (en) Potassium salt of (s
HK1070886B (en) Alkylammonium salts of omeprazole and esomeprazole
HK1051681B (en) New process for the preparation of the trihydrate of the magnesium salt of s-omeprazole

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20110830

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20120908

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20120908

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000